{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:55:02Z","timestamp":1791006902633,"version":"4.1.0"},"reference-count":22,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.26008","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:10:57Z","timestamp":1785363057000},"page":"199-208","source":"Crossref","is-referenced-by-count":0,"title":["Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group"],"prefix":"10.3960","volume":"66","author":[{"given":"Nobuhiko","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hayase","sequence":"additional","affiliation":[{"name":"Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Ikoma","sequence":"additional","affiliation":[{"name":"Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gifu Municipal Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Suzaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gifu Municipal Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gifu Municipal Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senji","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gifu Municipal Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gifu Prefectural General Medical Center, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Gifu Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fukuno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Takayama Hospital, Takayama, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Seino Kousei Hospital, Ibi-gun, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideko","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chuno Kosei Hospital, Seki, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, Matsunami General Hospital, Hashima-gun, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Matsunami General Hospital, Hashima-gun, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Matsunami General Hospital, Hashima-gun, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Matsunami General Hospital, Hashima-gun, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tsurumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Matsunami General Hospital, Hashima-gun, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Alaggio R, Amador C, Anagnostopoulos I, <i>et al.<\/i> The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720-1748.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Campo E, Jaffe ES, Cook JR <i>et al.<\/i> The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140: 1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Foley NC, Mehta-Shah N. Management of peripheral T-cell lymphomas and the role of transplant. Curr Oncol Rep. 2022; 24: 1489-1499.","DOI":"10.1007\/s11912-022-01310-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011; 2011: 623924.","DOI":"10.5402\/2011\/623924"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Younes A, Bartlett NL, Leonard JP <i>et al.<\/i> Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363: 1812-1821.","DOI":"10.1056\/NEJMoa1002965"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Horwitz S, O&apos;Connor OA, Pro B <i>et al.<\/i> Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019; 393: 229-240.","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Horwitz S, O&apos;Connor OA, Pro B <i>et al.<\/i> The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022; 33: 288-298.","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Takamatsu Y, Suzumiya J, Utsunomiya A <i>et al.<\/i> THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia\/lymphoma: a multicenter phase II study. Eur J Haematol. 2010; 84: 391-397.","DOI":"10.1111\/j.1600-0609.2010.01411.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Tomita N, Kodama F, Tsuyama N <i>et al.<\/i> Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients. Hematol Oncol. 2015; 33: 9-14.","DOI":"10.1002\/hon.2136"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Swerdlow SH, Campo E, Pileri SA <i>et al.<\/i> The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 . A predictive model for aggressive non-Hodgkin&apos;s lymphoma. N Engl J Med. 1993; 329: 987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Gallamini A, Stelitano C, Calvi R <i>et al.<\/i> Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004; 103: 2474-2479.","DOI":"10.1182\/blood-2003-09-3080"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Cheson BD, Pfistner B, Juweid ME <i>et al.<\/i> Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Cheson BD, Fisher RI, Barrington SF <i>et al.<\/i> Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32: 3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Tsurumi H, Hara T, Goto N <i>et al.<\/i> A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007; 25: 107-114.","DOI":"10.1002\/hon.815"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kida S, Fuji S, Morishima T <i>et al.<\/i> Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry. Int J Hematol. 2021; 114: 246-251.","DOI":"10.1007\/s12185-021-03150-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Iriyama N, Miura K, Takahashi H <i>et al.<\/i> The outcome of patients with peripheral T cell lymphoma treated with doxorubicin-based (CHOP) and pirarubicin-based regimen (THP-COP) regimen: a single institution experience. J Clin Exp Hematop. 2025; 65: 93-100.","DOI":"10.3960\/jslrt.25010"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Shibata Y, Hara T, Kasahara S <i>et al.<\/i> CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin. Hematol Oncol. 2017; 35: 163-171.","DOI":"10.1002\/hon.2262"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Hara T, Yoshikawa T, Goto H <i>et al.<\/i> R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial. Hematol Oncol. 2018; 36: 638-644.","DOI":"10.1002\/hon.2524"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Meesungnoen J, Jay-Gerin JP, Mankhetkorn S. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines. Can J Physiol Pharmacol. 2002; 80: 1054-1063.","DOI":"10.1139\/y02-132"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol. 1993; 11: 109-115.","DOI":"10.1200\/JCO.1993.11.1.109"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26: 4124-4130.","DOI":"10.1200\/JCO.2008.16.4558"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/3\/66_26008\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:34:55Z","timestamp":1791005695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/3\/66_26008\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.26008","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"26008"}}